Author
Liu, LinMesser, Karen
Baron, John A.
Lieberman, David A.
Jacobs, Elizabeth T.
Cross, Amanda J.
Murphy, Gwen
Martinez, Maria Elena
Gupta, Samir
Affiliation
Univ Arizona, Ctr Canc, Arizona Coll Publ HlthIssue Date
2016-08-12
Metadata
Show full item recordPublisher
SPRINGERCitation
A prognostic model for advanced colorectal neoplasia recurrence 2016, 27 (10):1175 Cancer Causes & ControlJournal
Cancer Causes & ControlRights
© Springer International Publishing Switzerland (outside the USA) 2016.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Following colonoscopic polypectomy, US Multisociety Task Force (USMSTF) guidelines stratify patients based on risk of subsequent advanced neoplasia (AN) using number, size, and histology of resected polyps, but have only moderate sensitivity and specificity. We hypothesized that a state-of-the-art statistical prediction model might improve identification of patients at high risk of future AN and address these challenges. Data were pooled from seven prospective studies which had follow-up ascertainment of metachronous AN within 3-5 years of baseline polypectomy (combined n = 8,228). Pooled data were randomly split into training (n = 5,483) and validation (n = 2,745) sets. A prognostic model was developed using best practices. Two risk cut-points were identified in the training data which achieved a 10 percentage point improvement in sensitivity and specificity, respectively, over current USMSTF guidelines. Clinical benefit of USMSTF versus model-based risk stratification was then estimated using validation data. The final model included polyp location, prior polyp history, patient age, and number, size and histology of resected polyps. The first risk cut-point improved sensitivity but with loss of specificity. The second risk cut-point improved specificity without loss of sensitivity (specificity 46.2 % model vs. 42.1 % guidelines, p < 0.001; sensitivity 75.8 % model vs. 74.0 % guidelines, p = 0.64). Estimated AUC was 65 % (95 % CI: 62-69 %). This model-based approach allows flexibility in trading sensitivity and specificity, which can optimize colonoscopy over- versus underuse rates. Only modest improvements in prognostic power are possible using currently available clinical data. Research considering additional factors such as adenoma detection rate for risk prediction appears warranted.Note
Published online: 12 August 2016; 12 Month Embargo.ISSN
0957-52431573-7225
PubMed ID
27517467Version
Final accepted manuscriptSponsors
Public Health Service Grants from the National Cancer Institute [CA-41108, CA-23074, CA95060, CA37287, CA104869, CA23108, CA59005, CA26852, 5R01CA155293]; Cooperative Studies Program, Department of Veterans Affairs; UCSD Department of Family Medicine and Public Health; United States Department of Veterans Affairs Health Services Research and Development Service of the VA Office of Research and Development [1 I01 HX001574-01A1]Additional Links
http://link.springer.com/10.1007/s10552-016-0795-5ae974a485f413a2113503eed53cd6c53
10.1007/s10552-016-0795-5
Scopus Count
Collections
Related articles
- Five-year risk for advanced colorectal neoplasia after initial colonoscopy according to the baseline risk stratification: a prospective study in 2452 asymptomatic Koreans.
- Authors: Chung SJ, Kim YS, Yang SY, Song JH, Kim D, Park MJ, Kim SG, Song IS, Kim JS
- Issue date: 2011 Nov
- Adenoma Detection Rate and Clinical Characteristics Influence Advanced Neoplasia Risk After Colorectal Polypectomy.
- Authors: Gupta S, Earles A, Bustamante R, Patterson OV, Gawron AJ, Kaltenbach TR, Yassin H, Lamm M, Shah SC, Saini SD, Fisher DA, Martinez ME, Messer K, Demb J, Liu L
- Issue date: 2023 Jul
- Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.
- Authors: Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK, US Multi-Society Task Force on Colorectal Cancer, American Cancer Society
- Issue date: 2006 May
- Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
- Authors: Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata Y, Uchiyama S, Hattori A, Nagase H, Kessoku T, Arimoto J, Matsuhashi N, Inayama Y, Yamanaka S, Taguri M, Nakajima A
- Issue date: 2016 Apr
- Development and validation of a risk score for advanced colorectal adenoma recurrence after endoscopic resection.
- Authors: Facciorusso A, Di Maso M, Serviddio G, Vendemiale G, Muscatiello N
- Issue date: 2016 Jul 14
